Clinical analysis of low-dos erituximab in the treatment of refractory idiopathic membranous nephropathy
Objective To explore the efficacy and safety of low-dose rituximab（RTX）for refractory idiopathic membranous nephropathy（IMN）.Methods From January 2017 to December 2018,32 cases of refractory IMN with positive anti-PLA2 R antibody were collected.They received low-dose RTX treatment and were followed...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Department of Journal of Clinical Nephrology
2021-01-01
|
| Series: | Linchuang shenzangbing zazhi |
| Subjects: | |
| Online Access: | http://www.lcszb.com/thesisDetails?columnId=57905525&Fpath=home&index=0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Objective To explore the efficacy and safety of low-dose rituximab（RTX）for refractory idiopathic membranous nephropathy（IMN）.Methods From January 2017 to December 2018,32 cases of refractory IMN with positive anti-PLA2 R antibody were collected.They received low-dose RTX treatment and were followed up for 1 year.Results The overall effective rate of low-dose RTX treatment for refractory IMN was 87.50% with a complete remission rate of 62.50% and a partial remission rate of 25.00%.After low-dose RTX treatment, CD19+B cell count, serum levels of total IgG and anti-PLA2 R antibody declined markedly（P<0.05）and disease severity was closely correlated with anti-PLA2 R antibody level.Adverse reactions of low-dose RTX treatment included agranulocytosis（n=2）,hypotension during infusion（n=2）and pulmonary infection（n=1）.Conclusion Low-dose rituximab is both effective and safe for refractory IMN. |
|---|---|
| ISSN: | 1671-2390 |